After that d etailed information of all the patients satisfying inclusi on criteria will be recorded in preset pro forma. This will include personal data, past history, medical history, drug history, clinical data like site, size, number, distribution of lesions. History of muscle weakness, bone pain, altered sensorium , anaphylaxis and immunos uppression will also be taken . In patients of group B s erum vitamin D level will be measured after 20 days of 3rd dose and 1 month after the last dose to ensure safe monitoring . Photographs of the lesions will be taken before the fi rst treatment session, in every treatment session a nd 3 months after last session. Group A Freeze‑dried MMR vaccine single -use vials stored at 2°C –8°C will be reconstituted with 0.5 mL of provided diluent (distilled water) as per manufacturer’s instruction immediately before intralesional use. If reconstituted vaccine is not used within 8 hours it mus t be discarded .37 All Group A patients will 24 receive intralesional injection of upto 0.5 mL of reconstitute d MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts with 3 1 G insulin syringe with beveled edge facing upward . Amount of injection on each wart will depend on the size of each wart. The i ntralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier .5 Group B All Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D 3 (600,000 IU; 15mg /ml) in each session after injection of IL lignocaine with 3 1 G insulin syringe . In cases of multiple warts, a maximum of 5 warts will be injected at a time. Amount of injection on each wart will depend on the size of each wart. The session will be done at 3 weekly interval s for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier. 22 Patient and physician global assessment using ‘Visual Analog S cale score’ and photographic comparison will be used to assess decrease in size and number of warts and thus the response to treatment . The clinical improvement will rated as complete response , excellent response, good response, poor or no response by the patient and physician global assessment using visual analog scale score at each visit taking baseline clinical photograph as controls . Immediate and late adverse effects of MMR vaccine and Vitamin D will be evaluated after each treatment session. Necessary investigations and intervention will be done if needed.